Completed PHASE2 INTERVENTIONAL 1-arm NCT03403777

Avelumab in Refractory Testicular Germ Cell Cancer.

Phase II Study of Avelumab in Multiple Relapsed/Refractory Testicular Germ Cell Cancer.

Sponsor: Merck KGaA, Darmstadt, Germany

Conditions Antineoplastic Agents Gonadal Disorders Molecular Mechanisms of Pharmacological Action Neoplasms Neoplasms, Germ Cell and Embryonal Testicular Diseases Testicular Neoplasms

Interventions Avelumab

Updated 8 times since 2018 Last updated: Mar 3, 2019 Started: Nov 15, 2017 Primary completion: Feb 28, 2019 Completion: Feb 28, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Antineoplastic Agents and Gonadal Disorders, this trial is completed. The trial is conducted by Merck KGaA, Darmstadt, Germany and has accumulated 8 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Apr 2019 — Jan 2021 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Mar 2019 — Apr 2019 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting

▶ Show 3 earlier versions

Jan 2019 — Mar 2019 [monthly]

Recruiting PHASE2
Jun 2018 — Jan 2019 [monthly]

Recruiting PHASE2
Feb 2018 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Nov 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck KGaA, Darmstadt, Germany
National Cancer Institute, Slovakia

Data source: National Cancer Institute, Slovakia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bratislava, Slovakia